JMP Securities analyst Constantine Davides initiated coverage of Privia Health with an Outperform rating and $27 price target. Privia has a diversified, capital-efficient business model, capable of serving both primary care physicians and specialists, the analyst tells investors in a research note. The firm views the company as a technology-enabled “arms merchant” for physician practices, providing services, strategies, and tools to optimize financial performance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRVA:
- Privia Health price target lowered to $38 from $43 at JPMorgan
- Privia Health price target lowered to $32 from $36 at Truist
- Privia Health price target lowered to $41 from $44 at Canaccord
- Privia Health price target lowered to $30 from $35 at TD Cowen
- Privia Health Reports Third Quarter 2023 Financial Results; Announces New Market Entry in South Carolina
